ImClone Revenue and Competitors
Estimated Revenue & Valuation
- ImClone's estimated annual revenue is currently $71.9M per year.
- ImClone's estimated revenue per employee is $155,000
Employee Data
- ImClone has 464 Employees.
- ImClone grew their employee count by -2% last year.
ImClone's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP | Reveal Email/Phone |
2 | VP HR | Reveal Email/Phone |
3 | AVP | Reveal Email/Phone |
4 | AVP, QA Compliance | Reveal Email/Phone |
5 | Director | Reveal Email/Phone |
6 | Laboratory Manager | Reveal Email/Phone |
7 | Bio Services | Reveal Email/Phone |
8 | QA Compliance Senior Engineer | Reveal Email/Phone |
9 | Principal Process Engineer | Reveal Email/Phone |
10 | senior research associate | Reveal Email/Phone |
ImClone Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is ImClone?
ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).
keywords:N/A
N/A
Total Funding
464
Number of Employees
$71.9M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ImClone News
ImClone Systems (Eli Lilly). This comprehensive Targeted Drug VEGFR2 Inhibitors for NSCLC Market report helps in determining the deficiencies and problems...
Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., and was a key member of their global...
... Current Therapies, Emerging Drugs, and Treatment Outlook | Companies ImClone, BeiGene, Novartis, Harbour BioMed, Tessa Therapeutics.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $88.4M | 464 | 11% | $3.5B |
#2 | $121.8M | 464 | -6% | N/A |
#3 | $127.6M | 464 | -4% | N/A |
#4 | $81.2M | 464 | N/A | N/A |
#5 | $142.7M | 464 | 9% | N/A |